Professor Karim Fizazi chairs a discussion with Professors Eleni Efstathiou, Nicholas Mottet, and Boris Hadaschek on the latest data presented at ASCO GU 2019 in San Francisco, specifically focused on patients with non-metastatic CRPC.

The group highlights the clinical landscape and treatment recommendations for these patients, and discuss how new data presented at ASCO GU, such the ARAMIS and SPARTAN studies, may impact treatment regimens and guidelines for this patient population.

Topics including the requirements and cost value of next generation PET imaging technology are also discussed, as well as the recommended preventative measures to manage bone health.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть